Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Dermatol Res ; 313(8): 679-684, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33125528

RESUMO

General guidelines for the maximum amounts of locally injected lidocaine exist; however, there is a paucity of data in the Mohs micrographic surgery (MMS) literature. This study aimed to determine the safety and adverse effects seen in patients that receive larger amounts of locally injected lidocaine. A retrospective chart review of 563 patients from 1992 to 2016 who received over 30 mL of locally injected lidocaine was conducted. Patient records were reviewed within seven postoperative days for complications. The average amount of anesthesia received was 40 mL, and the average patient weight was 86.69 kg. 1.4% of patients had a complication on the day of surgery, and 4.4% of patients had a complication within 7 days of the surgery. The most common complications were excessive bleeding/hematoma formation and wound infection. Only two complications could be attributable to local anesthetics. Gender, heart disease, hypertension, diabetes, and smoking were not significant risk factors for the development of complications. MMS is a safe outpatient procedure for patients that require over 30 mL of locally injected anesthesia. The safety of high volumes of lidocaine extends to patients with risk factors such as heart disease, hypertension, diabetes, and smoking.


Assuntos
Anestesia Local/efeitos adversos , Cirurgia de Mohs/efeitos adversos , Dor Processual/prevenção & controle , Complicações Pós-Operatórias/etnologia , Neoplasias Cutâneas/cirurgia , Idoso , Anestesia Local/métodos , Anestésicos Locais/administração & dosagem , Anestésicos Locais/efeitos adversos , Feminino , Humanos , Lidocaína/administração & dosagem , Lidocaína/efeitos adversos , Masculino , Pessoa de Meia-Idade , Dor Processual/etiologia , Complicações Pós-Operatórias/etiologia , Estudos Retrospectivos , Medição de Risco/estatística & dados numéricos , Fatores de Risco
4.
J Endocrinol ; 210(3): 271-84, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21642378

RESUMO

Rather than being a constitutive enzyme as was first suggested, endothelial nitric oxide synthase (eNOS) is dynamically regulated at the transcriptional, posttranscriptional, and posttranslational levels. This review will focus on how changes in eNOS function are conferred by various posttranslational modifications. The latest knowledge regarding eNOS targeting to the plasma membrane will be discussed as the role of protein phosphorylation as a modulator of catalytic activity. Furthermore, new data are presented that provide novel insights into how disruption of the eNOS dimer prevents eNOS uncoupling and the production of superoxide under conditions of elevated oxidative stress and identifies a novel regulatory region we have termed the 'flexible arm'.


Assuntos
Óxido Nítrico Sintase Tipo III/metabolismo , Óxido Nítrico/metabolismo , Sequência de Aminoácidos , Animais , Biopterinas/análogos & derivados , Biopterinas/metabolismo , Membrana Celular/metabolismo , Dimerização , Ativação Enzimática , Humanos , Modelos Moleculares , Simulação de Dinâmica Molecular , Dados de Sequência Molecular , Óxido Nítrico Sintase Tipo III/química , Fosforilação , Processamento de Proteína Pós-Traducional , Estrutura Quaternária de Proteína , Serina/metabolismo , Treonina/metabolismo , Tirosina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...